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Abstract The PTEN tumor suppressor gene encodes a phos-
phatidylinositol 3P-phosphatase that is inactivated in a high per-
centage of human tumors, particularly glioblastoma, melanoma,
and prostate and endometrial carcinoma. Previous studies
showed that PTEN is a seryl phosphoprotein and a substrate
of protein kinase CK2 (CK2). However, the sites in PTEN that
are phosphorylated in vivo have not been identi¢ed directly, nor
has the e¡ect of phosphorylation on PTEN catalytic activity
been reported. We used mass spectrometric methods to identify
Ser370 and Ser385 as in vivo phosphorylation sites of PTEN.
These sites also are phosphorylated by CK2 in vitro, and phos-
phorylation inhibits PTEN activity towards its substrate, PIP3.
We also identify a novel in vivo phosphorylation site, Thr366.
Following transient over-expression, a fraction of CK2 and
PTEN co-immunoprecipitate. Moreover, pharmacological inhi-
bition of CK2 activity leads to decreased Akt activation in
PTEN+/+ but not PTEN3/3 ¢broblasts. Our results contrast
with previous assignments of PTEN phosphorylation sites based
solely on mutagenesis approaches, suggest that CK2 is a phys-
iologically relevant PTEN kinase, and raise the possibility that
CK2-mediated inhibition of PTEN plays a role in oncogen-
esis. 6 2002 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The tumor suppressor gene PTEN plays a key role in mam-
malian growth control. PTEN is absent or mutated in a large
number of human tumors, especially glioblastoma, melanoma,
and prostate and endometrial carcinoma (reviewed in [1^4]).
With the exception of endometrial carcinomas [5], somatic
PTEN mutations typically are associated with more advanced
tumors [6^12]. Germline mutation of PTEN causes Cowden
disease [13,14], Lhermitte^Duclos disease [13], and Bannayan^
Zonana syndrome [15,16], which are characterized by benign
hamartomas of the thyroid, intestine, breast, and central ner-
vous system and a markedly increased cancer incidence.
Although homozygotic PTEN mutation in mice results in
early embryonic lethality, PTEN+/3 mice are tumor-prone,
exhibiting hyperplasia of the prostate, skin, and colon and an
increased incidence of breast, prostate and endometrial carci-
nomas, T cell lymphomas and leukemia [17^19]. Understand-
ing how PTEN is regulated should provide new insight into
cell signaling mechanisms and may suggest novel approaches
to treatment of PTEN-de¢cient tumors.
PTEN belongs to the dual speci¢city phosphatase (DSP)
family of protein phosphatases [6,7,20]. DSPs typically de-
phosphorylate phosphotyrosyl (pY), phosphothreonyl (pT)
and phosphoseryl (pS) residues in vitro, although they usually
are highly selective for particular pT-X-pY or pT-pY motifs in
vivo [21]. Although PTEN has DSP activity in vitro [22], its
physiological target is not a phosphoprotein, but instead, a
phospholipid: speci¢cally, the D3-phosphate group of phos-
phatidylinositol 3,4,5-triphosphate (PIP3) ([23^28], reviewed
in [1,29]). By dephosphorylating PIP3, PTEN antagonizes
growth-promoting and anti-apoptotic pathways that are
stimulated by phosphatidylinositol 3-kinase (PI3K), itself an
oncogene [30]. Cells lacking wild-type (WT) PTEN display
constitutive activation of Akt and other downstream targets
of the PI3K pathway, whereas ectopic over-expression of
PTEN inhibits several PI3K actions [18,24^27,31,32].
Surprisingly little is known about PTEN regulation. Besides
its catalytic domain, PTEN contains a C2 domain and a PDZ
binding motif. The C2 domain directs PTEN binding to phos-
pholipid vesicles in vitro, and mutations that abrogate vesicle
binding activity without a¡ecting catalysis disrupt PTEN
function in vivo [33]. However, there is no evidence for mod-
ulation of C2 domain/membrane association in response to
di¡erent stimuli. Several groups have reported association of
PTEN with PDZ domain-containing proteins; in some cases,
these potentiate the e¡ects of limiting amounts of PTEN on
PI3K-dependent functions in transient transfection assays
[34^36]. Mutations of the PDZ domain binding motif in
PTEN appear to impair some, but not all PTEN functions
[37]. The role of these interactions in tumor suppression re-
mains to be demonstrated.
Phosphorylation is a third possible mode of PTEN regula-
tion. Using mutagenesis approaches, two groups have sug-
gested that PTEN is phosphorylated at speci¢c C-terminal
seryl and threonyl residues. Vazquez and colleagues found
that deletion of the PTEN tail (residues 354^403) abrogated
most PTEN phosphorylation. They mutated every serine and
threonine in the tail to alanine, either singly or in clusters.
Because mutation of the cluster Ser380, Thr382, Thr383, and
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Ser385 signi¢cantly reduced incorporation of orthophosphate
into PTEN, they proposed that these are the predominant
phosphorylated residues [38]. Torres and Pulido [39] reported
that protein kinase CK2 (CK2) (formerly casein kinase II)
catalyzes phosphorylation of PTEN to high stoichiometry.
Mutation of residues Ser370 and Ser385 nearly abolished
CK2-induced phosphorylation and PTEN phosphorylation
in vivo, whereas mutations in residues Ser380, Thr382 and
Thr383 had a smaller e¡ect. Vazquez et al. [38] also reported
that mutation of Ser380, Thr382 or Thr383 to alanine resulted in
a PTEN protein that is less stable but more active in its ability
to block downstream targets of PIP3 and promote cell cycle
arrest, mimicking removal of the PTEN C-terminus [38,40]. In
contrast, Torres and Pulido found that mutation of Ser370,
Ser385, Ser380, Thr382 or Thr383 resulted in decreased PTEN
stability. Furthermore, PTEN instability was prevented by
treatment with the proteasome inhibitor MG132 [39,41].
Very recently, it was reported that mutation of Thr382 or
Thr383 [41] or substitution of alanine for residues Ser380,
Thr382, Thr383, and Ser385 increases PTEN association with
PDZ domain-containing proteins [42]. Thus, the prevailing
view is that phosphorylation keeps PTEN stable but less ac-
tive, whereas dephosphorylation activates PTEN and may en-
hance its interaction with PDZ domain-containing binding
partners, but also targets it for degradation. Notably, the sites
on PTEN that are phosphorylated in vivo have not been
identi¢ed directly, but only inferred from mutagenesis. Like-
wise how phosphorylation a¡ects PTEN catalytic activity has
not been analyzed.
Here, we use mass spectrometric methods to directly iden-
tify the major in vivo phosphorylation sites of PTEN as Ser370
and Ser385 ; Thr366 also is phosphorylated to a lower extent.
CK2 phosphorylates Ser370 and Ser385 to high stoichiometry
in vitro, and CK2 associates with PTEN in transient co-trans-
fection assays. Furthermore, CK2-catalyzed phosphorylation
inhibits PTEN activity against its physiologically relevant tar-
get, PIP3, and pharmacological inhibition of PTEN activity
leads to decreased Akt activity in a PTEN-dependent fashion.
2. Materials and methods
2.1. Cell culture, drug treatments and transfections
293-Pnx human embryonic kidney cells, a generous gift of Dr. Gary
Nolan, Stanford University Medical School (www.stanford.edu/
group/nolan/retroviral_systems/phx.html), U87-MG human glioblas-
toma cells (U87), and PTEN+/+ and PTEN3/3 ¢broblast lines de-
rived from teratomas derived from the corresponding embryonal stem
cells (supplied by Dr. P. Pandol¢, Memoral Sloan-Kettering Cancer
Center) [17] were maintained in Dulbecco’s modi¢ed Eagle’s medium
(DMEM) containing 2 mM L-glutamine and 10% fetal bovine serum
at 37‡C in a humidi¢ed 10% CO2 atmosphere. In some experiments,
the selective CK2 inhibitors apigenin (a plant £avonoid) [43] or emo-
din (an anthraquinone) [44] were prepared in dimethyl sulfoxide
(DMSO) and added to the culture media at the indicated concentra-
tions. Cells were transfected using Fugene-6 (Boehringer-Mannheim)
according to the manufacturer’s instructions. U87 cells expressing
wild-type PTEN were generated by retroviral infection using super-
natant from 293-Pnx cells previously transfected with a pBabepuro
plasmid expressing human PTEN cDNA. Puromycin-resistant clones
were isolated, and PTEN expression veri¢ed by immunoblotting. At
least three independent clones were tested for each parameter and
gave similar results.
2.2. Plasmids
pGEX-PTEN-351^403, pGEX-PTEN-366^403, and pGEX-PTEN-
376^403 were generated by polymerase chain reaction (PCR) using a
common downstream primer (5P-CGGAATTCAGACTTTTGTAAT-
TTGTGTATG-3P) and the following 5P primers: 5P-GCGCGGATC-
CGTAGAGGAGCCGTCAAATCC-3P (351^403), 5P-GCGCGGAT-
C CACACCAGATGTTAGTGAC-3P (366^403), 5P-GCGCGGA-
TCCCATTATAGATATTCTGAC-3P (376^403). The resultant PCR
products were cloned into the pGEX4T1 vector (Amersham/Pharma-
cia). PTEN point mutants were generated by overlap extension PCR
by using as £anking primers: 5P-CGGAATTCAGACTTTTG-
TAATTTGTGTATG-3P (upstream) and 5P-GAGGATCCACCAT-
GACAGCCATCATCAAAGA-3P (downstream), and the following
overlapping mutagenesis oligonucleotides: S370A: 5P-CACCA-
GATGTTGCTGACAATGAACC-3P and 5P-GGTTCATTGTCAG-
CAACATCTGGTG-3P ; S370D: 5P-CACCAGATGTTGATGACAA-
TGAACC-3P and 5P-GGTTCATTGTCATCAACATCTGGTG-3P ;
S385A: 5P-GACACCACTGACGCTGATCCAGAG-3P and 5P-CTC-
TGGATCAGCGTCAGTGGTGTC-3P ; S385D: 5P-GACACCACTG-
ACGATGATCCAGAG-3P and 5P-CTCTGGATCATCGTCAGTG-
GTGTC-3P ; S385T: 5P-GACACCACTGACACTGATCCAGAG-3P
and 5P-CTCTGGATCAGTGTCAGTGGTGTC-3P.
2.3. Production of recombinant PTEN
Cultures of bacteria (DH5K) expressing pGEX2T-PTEN (400 ml)
were induced at A600 = 0.5^1.0 with 0.1 mM isopropyl thiogalactose
(IPTG), incubated overnight at 25‡C, pelleted, and lysed in 25 mM
Tris^HCl (pH 8.0), 150 mM NaCl, 1 mM ethylenediamine tetraacetic
acid (EDTA) containing 0.1 mg/ml lysozyme, 5 mM dithiothreitol
(DTT), 20 Wg/ml leupeptin, 2 Wg/ml pepstatin A, 2 Wg/ml antipain,
4 Wg/ml aprotinin, and 40 Wg/ml phenylmethylsulfonyl £uoride. Triton
X-100 was added to a ¢nal concentration of 1% and the lysate was
sonicated and clari¢ed by centrifugation at 18 000Ug. Cleared lysates
were incubated with glutathione^agarose beads with rocking at 4‡C
overnight. The fusion protein was eluted into 20 mM reduced gluta-
thione (pH 8.0) for 10 min at 25‡C and dialyzed extensively against
storage bu¡er (50 mM HEPES (pH 7.4), 150 mM NaCl, 5 mM DTT,
50% glycerol).
2.4. In vitro kinase assays
Recombinant GST-PTEN or His-PTEN (a generous gift of Drs. S.
Dhe-Paganon and S. Shoelson; Joslin Diabetes Center) was labeled in
vitro with 500 U of CK2 (Calbiochem) in a 30 Wl reaction containing
200 WM adenosine triphosphate (ATP), 20 mM Tris^HCl, pH 7.5,
50 mM KCl, 10 mM MgCl2, and 1^10 WCi [Q-32P]ATP for 10 min
at 37‡C. Reactions were stopped with sodium dodecyl sulfate^polyac-
rylamide gel electrophoresis (SDS^PAGE) sample bu¡er, boiled, and
subjected to electrophoresis and autoradiography.
2.5. Antibodies, immunoprecipitations and immunoblotting
Anti-PTEN polyclonal antisera were generated by immunizing rab-
bits with GST-full length PTEN, and a⁄nity-puri¢ed antibodies were
prepared by passing antisera over GST-PTEN bound to A⁄-Gel 15
(Bio-Rad), according to standard procedures [45]. Anti-pAkt (Ser473)
antibodies were obtained from Santa Cruz Biotechnology and used as
recommended by the manufacturer. For whole-cell extracts, cells were
washed twice in phosphate-bu¡ered saline and lysed in Nonidet P-40
(NP-40) bu¡er (1% NP-40, 50 mM Tris^HCl (pH 7.4), 150 mM NaCl,
1 mM EDTA), containing 20 Wg/ml leupeptin, 2 Wg/ml pepstatin A,
2 Wg/ml antipain, 4 Wg/ml aprotinin, 40 Wg/ml phenylmethylsulfonyl
£uoride (PMSF), 2 mM sodium £uoride, 2 mM sodium vanadate, and
25 mM L-glycerol phosphate. Lysates were cleared by centrifugation
at 4‡C for 10 min. Immunoprecipitations and immunoblotting were
performed as described previously [46], except that following immu-
noprecipitation, beads were washed once in 20 mM Tris^HCl (pH
8.0), 250 mM NaCl, 1 mM EDTA, 0.5% NP-40, and four times in
20 mM Tris^HCl (pH 8.0), 100 mM NaCl, 1 mM EDTA, 0.5% NP-
40.
2.6. Lipid phosphatase assays
PIP3 radiolabeled at the D-3 position was generated by incubating
phosphatidylinositol 4,5-bisphosphate (Sigma) in 50 WM ATP, 20 WCi
[Q-32P]ATP, 10 mM MgCl2, and baculovirus-puri¢ed PI3K (a gener-
ous gift of Dr. L. Cantley, Beth Israel-Deaconess Medical Center) for
60^120 min at 25‡C in a total volume of 50 Wl. Reactions were termi-
nated by the addition of 1 N HCl (80 Wl), and lipids were extracted
into 160 Wl chloroform:methanol (1:1). Aliquots of radiolabeled PIP3
were dried under N2, sonicated in 10 Wl of 10 mM Tris^HCl, pH 7.5,
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and used in 25 Wl reactions containing 50 mM Tris^HCl, pH 7.5,
50 mM NaCl, 2 mM DTT and recombinant PTEN. Reactions were
incubated at 37‡C for 5^10 min and stopped with acid-washed char-
coal (800 Wl). A fraction of the supernatant (600^700 Wl) was used to
quantify phosphate release by scintillation counting.
For assaying the e¡ect of CK2-catalyzed phosphorylation on PTEN
activity, kinase reactions were terminated by the addition of 5 mM
EDTA and chilled on ice. Reactions were adjusted to the appropriate
Tris^HCl, NaCl, and DTT concentrations for lipid phosphatase as-
says, radiolabeled PIP3 was added, and incubation and analysis were
carried out as described above.
2.7. GST fusion protein binding assays
Lysates from asynchronous U87 cells were prepared as above. Ly-
sate (2 mg) was incubated with 20 Wg of fusion protein at 4‡C for
3.5 h. The beads were washed as above, and bound proteins were
resolved by SDS^PAGE and analyzed by immunoblotting.
2.8. Metabolic labeling and phosphoamino acid analysis
U87 cells expressing wild-type PTEN were radiolabeled at 70%
con£uence with 1 mCi of [32P]orthophosphate/10 cM plate in phos-
phate-free DMEM for 4 h. PTEN immunoprecipitates (prepared as
described above) were resolved by SDS^PAGE. Following electro-
blotting onto Immobilon-P (Millipore), radiolabeled PTEN was hy-
drolyzed in 6 N HCl, and phosphoamino acid analysis was performed
as described [47].
2.9. Mass spectrometric analysis of phosphopeptides
Following SDS^PAGE, gels were stained with Coomassie blue,
destained, and the PTEN band was excised and subjected to reduc-
tion, carboxyamidomethylation, and digestion with trypsin. Tryptic
peptides were analyzed by microcapillary reverse-phase high-perfor-
mance liquid chromatography (HPLC) nano-electrospray tandem
mass spectrometry (WLC-MS/MS) on a ThermoFinnigan LCQ
DECA quadrupole ion trap mass spectrometer.
Two strategies were used to enhance the detection of low stoichi-
ometry-phosphorylated peptides. In one, phosphorylated peptides
were selectively enriched by performing bimodal chromatography on
a Fe3þ metal a⁄nity/reverse-phase microcolumn directly coupled to
the ion trap MS. The ion trap repetitively surveyed MS (395^
1295 m/z), executing data-dependent scans on the three most abun-
dant ions in the survey scan, allowing high-resolution (zoom) scans to
determine charge state and exact mass and MS/MS spectra for peptide
sequence information. MS/MS spectra were acquired with a relative
collision energy of 30% and an isolation width of 2.5 Da. Recurring
ions were dynamically excluded. After database correlation with SE-
QUEST, phosphorylated peptides were con¢rmed by manual, de novo
interpretation of the MS/MS spectra using FuzzyIons [48]. Second sets
Fig. 1. Phosphoamino acid analyses. A: Two-dimensional phosphoamino acid analysis of PTEN isolated in vivo (left) or phosphorylated in vi-
tro by CK2 (right). B: Phosphoamino acid analyses of WT and PTEN mutants phosphorylated by CK2. Note shift in ratio of phosphoserine
and phosphothreonine, particularly in the S370T, S385T mutant. Cold phosphoamino acid standards were used to determine the locations of
phosphotyrosine (Y), phosphothreonine (T), and phosphoserine (S), as indicated.
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of WLC-MS/MS experiments were conducted for each tryptic peptide
containing the putative phosphorylation. In these targeted ion MS/
MS (TIMM) experiments, the predicted m/z of the peptide is targeted
for the entire chromatographic run. This signi¢cantly increases MS/
MS sensitivity by capturing only the peptide of interest while remov-
ing interfering chemical and peptidic background.
3. Results and discussion
3.1. Direct identi¢cation of PTEN phosphorylation sites
Consistent with previous publications [38,39], anti-PTEN
immunoprecipitations from PTEN-expressing cells metabol-
ically labeled with [32Pi]orthophosphate contained a 32P-la-
beled protein of size predicted for PTEN (data not shown).
Phosphoamino acid analysis revealed that PTEN is phosphor-
ylated predominantly on seryl residues, although there was a
small amount of threonyl phosphorylation (Fig. 1A). To di-
rectly identify PTEN phosphorylation sites, GST-PTEN was
expressed in 293-Pnx cells, puri¢ed on glutathione agarose
beads, and subjected to microcapillary HPLC tandem mass
spectrometry (WLC-MS/MS) with bimodal chromatography
and targeted ion MS/MS (TIMM) analyses. In such analyses,
each of the phosphorylated peptides is subjected to collision-
induced dissociation in the mass spectrometer, and the result-
ing products of that fragmentation are recorded as a mass
spectrum that can be assigned to a speci¢c linear sequence
of amino acids. For a given peptide, each possible phosphor-
ylation site generates di¡erent and unique product ions in the
MS/MS spectrum. For each peptide in Table 1, we observed
product ions that were characteristic of addition of phosphate
only at the sites indicated. This analysis unambiguously iden-
ti¢ed Ser370, Ser385 and Thr366 as in vivo phosphorylation
sites.
Because the PTEN C-terminus contains CK2 consensus
phosphorylation sites, and because CK2 over-expression [49]
or loss of PTEN (see Section 1) can cause T cell lymphomas,
we asked whether CK2 could phosphorylate and/or regulate
PTEN. Indeed, CK2 phosphorylated a glutathione-S-transfer-
ase-PTEN fusion protein (GST-PTEN) to a stoichiometry of
Fig. 2. In vitro phosphorylation of PTEN by CK2. A: Phosphorylation of PTEN truncation mutants. GST fusion proteins containing the indi-
cated PTEN amino acids or GST-full length PTEN (‘wild-type’) were used as substrates for in vitro kinase assays with CK2. The arrows indi-
cate the expected positions of the various GST fusion proteins (indicated at the top of each lane). Molecular weight markers also are shown.
The autoradiogram in the left panel was exposed approximately ¢ve times longer than the right panel (compare intensity of GST-WT bands).
(3) no exogenous substrate. Note CK2 autophosphorylation in the left panel, which is diminished by the presence of the good substrate, GST-
PTEN (‘wild-type’). CK2 phosphorylation is not evident in the autoradiogram in the right panel, because of the shorter exposure time and be-
cause all of the GST fusion proteins in this experiment were good CK2 substrates. B: Phosphorylation of PTEN point mutants. GST fusion
proteins to WT PTEN and the indicated PTEN mutants were phosphorylated by CK2. Autoradiograms and Coomassie stains for protein load-
ing are shown.
Table 1
Mass spectrometry analysis of PTEN phosphorylation
Peptide no. Peptide Phosphorylated residue
1 TVEEPSNPEASSSTSVpTPDVSDNEpDHYRa T366
2 TVEEPSNPEASSSTSVTPDVpSDNEPDHYRb S370
3 YSDTTDpSDPENEPFDEDQHTQITKc S385
4 YSDTTDpSDPENEPFDEDQHTQITKVb S385
aObserved in vivo.
bObserved both in vitro and in vivo.
cObserved in vitro.
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s 1 mol phosphate/mol protein, consistent with the observa-
tions of Torres and Pulido [39]. CK2-phosphorylated PTEN
was predominantly seryl phosphorylated with lesser amounts
of threonyl phosphorylation (Fig. 1A).
We con¢rmed that CK2 phosphorylates PTEN within its C-
terminus by using nested GST-PTEN fusion proteins. CK2
did not phosphorylate PTEN lacking residues 360^403 (Fig.
2A; left panels). However, CK2 phosphorylated GST-PTEN-
351^403 and GST-PTEN-366^403 equivalently, whereas GST-
PTEN-376^403 was phosphorylated to a lower extent (Fig.
2A, right panels ; note the higher amount of GST-PTEN-
376^403 fusion protein in the Coomassie stain). These data
indicate that at least one phosphorylated residue resides in the
region between amino acids 366 and 376, with an additional
phosphorylated residue(s) downstream of position 376 (Fig.
2A).
To directly identify the residues phosphorylated by CK2, in
vitro phosphorylated PTEN was subjected to WLC-MS/MS
analysis. Both Ser370 and Ser385 were identi¢ed as CK2 phos-
phorylation sites (Table 1). Thus, the two seryl residues of
PTEN phosphorylated in vivo are identical to those phos-
phorylated to high stoichiometry by CK2 in vitro. Conceiv-
ably, the third in vivo phosphorylation site, Thr366, also is
phosphorylated by CK2, because phosphoamino acid analysis
showed that CK2 phosphorylation of PTEN is partially on
threonyl residues (Fig. 1A). Mass spectrometric analysis did
not detect this residue in PTEN phosphorylated in vitro.
Although this technology is extremely sensitive, low stoichio-
metric events can be missed. A mixture of singly phosphory-
lated Thr366 and Ser370 peptides might be expected to co-chro-
matograph and co-fragment in the WLC-MS/MS analysis. The
more abundant peptides would dominate, masking the se-
quence interpretation of the minor component. However, we
were able to identify the Thr366-phosphorylated peptide in
PTEN in vivo (Table 1). Since it usually is easier to detect
phosphorylation events in vitro compared to in vivo, we sus-
Fig. 3. Association of PTEN and CK2. A: PTEN interacts with CK2 in vitro. The indicated GST-PTEN fusion proteins or GST were incuba-
ted with 2 mg U87 cell lysate (+) or lysis bu¡er alone (3) to exclude non-speci¢c cross-reactivity of the GST fusion protein with anti-CK2
antibodies. Bound proteins were collected, resolved by SDS^PAGE and immunoblotted with anti-CK2 antibodies. Also shown is anti-CK2 im-
munoblot of 50 Wg of total U87 cell lysate (TCL). B, C: PTEN interacts with CK2 in vivo. 293-Pnx cells were transfected with expression plas-
mids for HA-CK2 and GST-PTEN separately or together. TCL and proteins bound to glutathione^agarose were resolved by SDS^PAGE and
immunoblotted with anti-HA antibodies, as indicated (B). Alternatively, anti-HA immunoprecipitates were prepared, and bound proteins and
TCL were immunoblotted with anti-GST antibodies (to detect GST-PTEN) or anti-HA antibodies (to detect CK2), as indicated (C).
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pect that another kinase is responsible for the low stoichiom-
etry phosphorylation of Thr366 in vivo (and that CK2 phos-
phorylates another threonyl residue in vitro). Notably, Thr366
is followed by a prolyl residue, and does not conform to the
CK2 consensus, making it far more likely that this site is the
target of a prolyl-directed kinase.
Surprisingly, following mutagenesis of PTEN residues
Ser370 and/or Ser385 to alanine or aspartic acid, CK2 remained
capable of phosphorylating the mutant PTEN protein (Fig.
2B). Thus, when its preferred sites are mutated, CK2 can
phosphorylate other sites in PTEN. However, only Thr366,
Ser370 and Ser385 were detected in PTEN in vivo by MS/
MS, suggesting that these ‘default’ sites are not signi¢cantly
phosphorylated in the wild-type protein. Phosphoamino acid
analysis of doubly-point-mutated PTEN (either PTEN (Ala370
and Ala385) or PTEN (Asp370 and Asp385)) suggests that at
least some of the other residues phosphorylated by CK2 after
mutagenesis of Ser370 and Ser385 are threonines, because the
ratio of seryl to threonyl phosphorylation changed from pri-
marily seryl phosphorylation (roughly 80%) to nearly equiv-
alent seryl and threonyl phosphorylation (compare Fig. 1A,
right panel with Fig. 1B, lower left panel). Mutation of Ser385
alone resulted in primarily threonyl phosphorylation of PTEN
by CK2 (Fig. 1B, upper right panel), whereas comparable
mutations at Ser370 resemble the phosphoamino acid ratio
of wild-type PTEN (compare Fig. 1A with Fig. 1B). CK2
phosphorylation of PTEN containing both Ser370 and Ser385
converted to threonine revealed a switch from primarily seryl
to primarily threonyl phosphorylation, con¢rming that these
residues are the preferred substrates for CK2 (compare Fig.
1A with Fig. 1B, lower right panel).
Previous studies showed that mutation of Ser380, Thr382 or
Thr383 decreases PTEN stability [38,39] and increase its ability
to inhibit downstream targets of PIP3 in transient transfec-
tions [38], leading to the conclusion that phosphorylation of
these sites regulates PTEN. However, our direct sequence
analysis of PTEN phosphopeptides reveals no signi¢cant
phosphorylation of these residues either in vitro (with CK2)
or in vivo. Moreover, phosphoamino acid analysis reveals
only a minor amount of threonyl phosphorylation of PTEN
(Fig. 1A), which presumably is due, at least in part, to phos-
phorylation at Thr366 (Table 1). Failure to detect phosphory-
lation of Thr382 or Thr383 (or, for that matter, Ser380) by mass
spectrometry does not exclude the possibility that one or both
of these residues is phosphorylated, particularly if either is
phosphorylated at low stoichiometry (see above). However,
it is di⁄cult to see how sub-stoichiometric threonyl phosphor-
ylation (Fig. 1A, B) could regulate the stability of the entire
pool of PTEN. Moreover, since Ser380 lies within the same
tryptic peptide as Ser385, it should have been detectable by
MS/MS were it phosphorylated to comparable levels. For
these reasons, we suspect that mutation of Ser380, Thr382
and/or Thr383 probably a¡ects the ability of Ser370 and/or
Ser385, the real in vivo phosphorylation sites, to be phosphor-
ylated and/or improves recognition of PTEN by an F-box
protein required to target it to the proteasome. Notably, Vaz-
quez et al. [38] found that mutation of Ser385 to alanine had
no e¡ect on PTEN stability, whereas Torres and Pulido [39]
reported decreased stability of either this mutant or a mutant
of the other major PTEN phosphorylation site identi¢ed here,
Ser370. It is not obvious how to explain this discrepancy.
However, our data indicate that CK2 can phosphorylate sec-
ondary sites on PTEN when the primary sites are mutated
(Figs. 1B and 2B); conceivably, this could occur to di¡erent
extents in di¡erent cell systems (perhaps dependent on the
levels of expression of PTEN and the activity of CK2). Re-
gardless, our results emphasize the danger of relying on muta-
genesis approaches alone for the identi¢cation of phosphory-
lation sites and/or for inferring the consequences of
phosphorylation.
3.2. CK2 and PTEN physically associate
To test whether CK2 and PTEN can physically associate,
we incubated GST-PTEN with U87 cell lysates, collected
bound proteins on glutathione agarose beads and performed
CK2 immunoblots. A small amount of CK2 bound to GST-
PTEN, but not to GST in this assay (Fig. 3A). CK2 interacted
similarly with catalytically inactive PTEN (C124S) and PTEN
mutants that had one or more of the preferred CK2 phos-
phorylation sites altered (Fig. 3A and data not shown). We
asked whether CK2 and PTEN associate in vivo by co-trans-
fecting expression plasmids for each into 293-Pnx cells and
performing reciprocal co-immunoprecipitations. Indeed, CK2
(HA-tagged) could be detected in PTEN immunoprecipitates
and PTEN (GST-tagged) could be detected in CK2 immuno-
precipitates (Fig. 3B, C). Thus, PTEN and CK2 can form a
complex in vitro and in vivo. However, despite multiple at-
tempts, we did not detect signi¢cant co-immunoprecipitation
of endogenous PTEN and CK2; whether this re£ects inad-
equacy of our reagents or a low-a⁄nity interaction between
PTEN and CK2 as observed with most enzyme/substrate
complexes, remains unclear.
Fig. 4. CK2 phosphorylation suppresses PTEN activity. Following
phosphorylation by CK2, PTEN activity against radiolabeled PIP3
substrate was assessed. Shown is the mean and standard error of
seven independent experiments; each experiment was normalized
such that the activity of unphosphorylated PTEN is set at 100%.
The stoichiometry of phosphorylation of PTEN was approximately
2 mol P/mol PTEN. The di¡erence in activity of phosphorylated
PTEN compared to unphosphorylated PTEN is highly signi¢cant
(P6 0.0005; Student’s t-test).
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3.3. Phosphorylation by CK2 inhibits PTEN activity
Following phosphorylation by CK2, the ability of PTEN to
dephosphorylate PIP3 was reduced by approximately 30%
(Fig. 4) compared with PTEN subjected to a mock kinase
reaction without CK2. These results argue that phosphoryla-
tion of PTEN by CK2 directly suppresses PTEN catalytic
activity. Because, as indicated above, mutation of the pre-
ferred CK2 sites results in new (probably non-physiological)
sites of CK2 phosphorylation, we could not assess whether
phosphorylation of Ser370, or Ser385, or both is responsible
for inhibition of PTEN activity.
How phosphorylation inhibits PTEN remains unclear. An
intriguing possibility is raised by the acidic nature of CK2
phosphorylation sites and PTEN’s physiological substrate,
PIP3. The PTEN catalytic domain is designed speci¢cally to
accommodate highly negatively charged residues [33], and the
only reasonable in vitro peptide substrate of PTEN (polyGlu-
Tyr) is highly negatively charged [22]. This suggests that the
phosphorylated tail of PTEN (368-DVpSDNEPDHYRYS-
DTTDpSDPENE-390) may serve as a pseudosubstrate.
Although phosphorylation by CK2 a¡ects PTEN’s activity
directly, phosphorylation also could a¡ect PTEN’s cellular
localization and/or its ability to associate with other proteins.
PTEN has been shown to interact via its extreme C-terminus
with PDZ domain-containing proteins, including members of
the MAGUK family. The sites that are phosphorylated by
CK2 are in fairly close proximity (15^30 amino acids) to the
PDZ domain interacting residues and indeed, recent data sug-
gest that mutations within this region can a¡ect PTEN inter-
actions with PDZ-containing proteins [41,42].
3.4. CK2 regulates the Akt pathway in a PTEN-dependent
fashion
Our results, together with previous studies [38,39], strongly
suggest that CK2 is a physiologically relevant PTEN kinase
and that CK2-mediated phosphorylation inhibits PTEN func-
tion. To assess the functional relevance of phosphorylation of
PTEN by CK2, PTEN+/+ and PTEN3/3 ¢broblast lines
were treated with the structurally unrelated, CK2-selective
inhibitors apigenin or emodin. Since Akt phosphorylation is
negatively regulated by PTEN, phospho-Akt (pAkt) levels
were used as an indirect measure of PTEN bioactivity. As
expected, cells lacking PTEN (Fig. 5A, B; left lanes) had
constitutively high pAkt. Importantly, there was no change
in pAkt following inhibition of CK2 with either apigenin
(Fig. 5A) or emodin (Fig. 5B). In contrast, PTEN+/+ cells
Fig. 5. Inhibition of CK2 reduces pAkt levels in a PTEN-dependent manner. Randomly growing PTEN3/3 or PTEN+/+ ¢broblasts were incu-
bated with increasing doses of the selective CK2 inhibitors apigenin (A) or emodin (B). After 3 h, cells were lysed and immunoblotted for the
indicated antigens. Densitometry was performed and pAkt levels were normalized to L-actin and compared to cells with no drug treatment set
at 100% (C and D). Note that PTEN3/3 cells have no immunoreactive PTEN and although their basal pAkt levels are much higher than in
PTEN+/+ cells, they are not altered in response to the CK2 inhibitors. In contrast, PTEN+/+ cells have lower basal levels of pAkt, and pAkt
is further reduced in a dose-dependent manner in response to CK2 inhibition. These data are consistent with a model in which CK2 inhibits
PTEN in vivo, and relief of CK2-mediated inhibition leads to increased PTEN activity and consequently decreased Akt activity.
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(Fig. 5A, B; right lanes) had lower basal levels of pAkt, and
pAkt levels decreased further with apigenin (Fig. 5A) or emo-
din treatment (Fig. 5B). At the highest drug doses, a reduction
in PTEN protein level was observed. Thus, CK2 can regulate
Akt activity, but only in the presence of wild-type PTEN.
These data strongly support the hypothesis that CK2 regu-
lates PTEN activity and, possibly, stability in vivo (which in
turn regulates PIP3 levels and thereby Akt phosphorylation).
The e¡ect of CK2 on PTEN stability is reminiscent of the
stabilizing e¡ect of CK2-mediated phosphorylation of L-cat-
enin [50] and c-myc (Channavajhala and Seldin, submitted),
and raises the possibility that a general role for CK2-mediated
phosphorylation may be to regulate target protein stability.
CK2 is upregulated in many human cancers, as well as in
cattle infected with the parasite Theileria parva. Transgenic
expression of CK2 in lymphocytes [49,51] or the mammary
gland [52] promotes neoplastic transformation, supporting a
causal role for increased CK2 activity in oncogenesis. CK2 is
purported to have multiple cellular targets and to a¡ect many
fundamental cell processes (reviewed in [53]) but the key pro-
teins that mediate oncogenesis by CK2 remain unknown. In-
terestingly, lymphomagenesis in CK2 transgenic mice is accel-
erated by co-expression of the CK2 substrates myc [51] or by
loss of p53 [54]. Our results, together with those of earlier
workers, strongly suggest that PTEN is another key target
of CK2-mediated oncogenesis. In this regard, CK2 over-ex-
pression might be expected to potentiate tumorigenesis in a
heterozygotic PTEN+/3 background. Moreover, by inactivat-
ing endogenous PTEN, CK2 over-expression might bypass
the need for PTEN inactivation in tumors that typically ex-
press wild-type PTEN, such as breast carcinomas [55]. Deter-
mination of whether CK2 over-expression or PTEN absence,
but not both, occur in the same tumor samples should clarify
this issue and determine the importance of this newly identi-
¢ed regulation of PTEN.
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